標題：Tafasitamab，CAS:1422527-84-1， AntibodySystem Laboratories

貨號：DHD10803

產(chǎn)品鏈接：

別名：CD19, MOR-00208, MOR-208, XENP-5574, XMP-5574, XmAb-5574, Xmab-CD19, CAS: 1422527-84-1

簡介：

Tafasitamab (XmAb5574) 是一種 Fc 修飾的人源化單克隆抗體，可與人 B 細胞表面抗原 CD19 結(jié)合。

形態(tài)：Liquid

保存：0.01M PBS, pH 7.4.

濃度：1 mg/ml

純度：>95%

克隆性：Monoclonal

亞型：IgG1-G2-kappa

應(yīng)用：Research Grade Biosimilar

靶點：CD19

應(yīng)用范圍：類似物，陽性對照抗體

產(chǎn)地：France

標記物：Unconjugate

品牌：AntibodySystem

抗原來源：Mammalian cells

適應(yīng)物種：Human

標識物：Unconjugate

保存條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -217°C long term.

參考文獻：

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. PMID: 32511983
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. PMID: 34196165
Tafasitamab: First Approval. PMID: 32946059
Tafasitamab. PMID: 33355731
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. PMID: 33554668
Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison. PMID: 35403948
Tafasitamab-cxix. PMID: 33016999
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. PMID: 34433649
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. PMID: 35674661
The use of tafasitamab in diffuse large B-cell lymphoma. PMID: 34285786
Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma. PMID: 34586105
Diffuse large B-cell lymphoma: new targets and novel therapies. PMID: 33820908
Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls. PMID: 35861632
Tafasitamab at the blood-brain barrier. PMID: 36691708
Treatment strategies for patients with diffuse large B-cell lymphoma. PMID: 35933930
Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy. PMID: 35348812
Antibodies to watch in 2020. PMID: 31847708
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients. PMID: 33230948
The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma. PMID: 34805769
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. PMID: 33202794
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. PMID: 34414843
Real-world data in drug development strategies for orphan drugs: Tafasitamab in B-cell lymphoma, a case study for an approval based on a single-arm combination trial. PMID: 35218926
Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis. PMID: 35585701
Economic evaluation of polatuzumab-bendamustine-rituximab vs. tafasitamab-lenalidomide in transplant-ineligible R/R DLBCL. PMID: 34866523
Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies. PMID: 34945817
Follicular lymphoma: The long and winding road leading to your cure? PMID: 35908982
Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab. PMID: 35454825
Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed Lymphoma. PMID: 34776401
New and emerging therapies for the treatment of relapsed/refractory diffuse large B-cell lymphoma. PMID: 35469489
CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas. PMID: 34949132
Transformed Waldenstr?m Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report. PMID: 36636536
A phase 2a, single-arm, open-label study of tafasitamab, a humanized, Fc-modified, anti-CD19 antibody, in patients with relapsed/refractory B-precursor cell acute lymphoblastic leukemia. PMID: 34343354
Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. PMID: 36648324
Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL. PMID: 34354920
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. PMID: 34741682
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study. PMID: 34779360
How to Sequence Therapies in Diffuse Large B-Cell Lymphoma Post-CAR-T Cell Failure. PMID: 34697650
Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options. PMID: 36510607
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. PMID: 34407608
Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation. PMID: 35989138
Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy. PMID: 35184664
Treatments for relapsed-refractory diffuse large B-cell lymphoma: comparison of overall survival outcomes observed with four novel agents. PMID: 35856357
Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody. PMID: 36726938
Lenalidomide in DLBCL: are we past the cell of origin? PMID: 33989279
[Current status and future prospects of diffuse large B-cell lymphoma treatment]. PMID: 36198538
Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma. PMID: 35037773
Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL. PMID: 36873252
Incorporating Novel Targeted and Immunotherapeutic Agents in Treatment of B-Cell Lymphomas. PMID: 33770460
Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody. PMID: 36119088
Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis. PMID: 36915243
Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering. PMID: 33212776
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis. PMID: 35820018
Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma. PMID: 34505550
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. PMID: 29444231
The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients. PMID: 23277329
Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report. PMID: 27178351